Prime Medicine, Inc.
PM359
Chronic Granulomatous Disease (CGD)
Resolved
218days ago
Phase 2 readout · Dec 1, 2025
What's at stake
Phase 2 trial results for PM359 in Chronic Granulomatous Disease (CGD) are due Dec 1, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“In December 2025, Prime Medicine announced the publication of Phase 1/2 clinical data with PM359 in the New England Journal of Medicine (NEJM). The data, which were also presented in a poster session at the 67 th American Society of Hematol”